PropThink: Management says Ariad is Well-Prepared for Ponatinib Launch

[ACN Newswire] – By Jake KingOn the heels of ponatinib’s Priority Review announcement , Ariad Pharmaceuticals (NASDAQ:ARIA) reported 3Q financial results Wednesday, and on its related conference call emphasized the preparation … more

View todays social media effects on PFE

View the latest stocks trending across Twitter. Click to view dashboard